A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

What is the purpose of this trial?

CC-90002-ST -001 is an open-label, Phase 1, dose escalation and expansion clinical study in subjects advanced, refractory solid and hematologic cancers.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Celgene Corporation

Start Date: 09/20/2017

End Date: 01/31/2018

Last Updated: 06/06/2018

Study HIC#: 2000020507

Get Involved

For more information about this study, contact:
Laura Leary
laura.leary@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image